157 related articles for article (PubMed ID: 38089085)
41. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
42. Ferroptosis and WDFY4 as novel targets for immunotherapy of lung adenocarcinoma.
Huang L; Zhong L; Cheng R; Chang L; Qin M; Liang H; Liao Z
Aging (Albany NY); 2023 Sep; 15(18):9676-9694. PubMed ID: 37728413
[TBL] [Abstract][Full Text] [Related]
43. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
44. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
45. The characterization of tumor microenvironment infiltration and the construction of predictive index based on cuproptosis-related gene in primary lung adenocarcinoma.
Li K; Wu LL; Wang H; Cheng H; Zhuo HM; Hao Y; Liu ZY; Li CW; Qian JY; Li ZX; Xie D; Chen C
Front Oncol; 2022; 12():1011568. PubMed ID: 36505852
[TBL] [Abstract][Full Text] [Related]
46. m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
Li F; Wang H; Huang H; Zhang L; Wang D; Wan Y
Front Genet; 2020; 11():994. PubMed ID: 33193582
[TBL] [Abstract][Full Text] [Related]
47. Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.
Gao C; Li H; Ma W; Zhang Q; Liu C; Liu L; Zhuang J; Sun C
J Immunol Res; 2022; 2022():7519838. PubMed ID: 36061307
[TBL] [Abstract][Full Text] [Related]
48. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
49. KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway.
Chen X; Lu T; Cai Y; Han Y; Ding M; Chu Y; Zhou X; Wang X
Cell Mol Biol Lett; 2023 Apr; 28(1):32. PubMed ID: 37076815
[TBL] [Abstract][Full Text] [Related]
50. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
[TBL] [Abstract][Full Text] [Related]
51. KIAA1429 facilitates progression of hepatocellular carcinoma by modulating m6A levels in HPN.
Meng Y; Yang W; Li J; Chai W
Heliyon; 2023 Nov; 9(11):e22084. PubMed ID: 38058614
[TBL] [Abstract][Full Text] [Related]
52. Function and prognostic value of N6-methyladenosine-modified RNAs in lung adenocarcinoma.
Liu J; Zheng Z; Zhong J
J Gene Med; 2023 Jan; 25(1):e3454. PubMed ID: 36282144
[TBL] [Abstract][Full Text] [Related]
53. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
54. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
[TBL] [Abstract][Full Text] [Related]
55. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
[TBL] [Abstract][Full Text] [Related]
56. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
57. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
58. SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
Zhang X; Wu Z; Ma K
BMC Cancer; 2022 Apr; 22(1):406. PubMed ID: 35421944
[TBL] [Abstract][Full Text] [Related]
59. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
Front Immunol; 2022; 13():960738. PubMed ID: 36032135
[TBL] [Abstract][Full Text] [Related]
60. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
